Unknown

Dataset Information

0

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.


ABSTRACT: Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma.Patients had ECOG performance status 0-2 and normal organ function. Dacarbazine was administered on day 1 and dasatinib on day 2 through 19 of each 21-day cycle. Both were escalated from 50 mg b.i.d. of dasatinib and 800 mg m(-2) of dacarbazine. Available pre-treatment biopsies were sequenced for BRAF, NRAS, and C-Kit mutations.Dose-limiting toxicity was reached at dasatinib 70 mg b.i.d./dacarbazine 1000 mg m(-2), and was predominantly haematological. In 29 patients receiving dasatinib 70 mg b.i.d., the objective response rate (ORR) was 13.8%, the clinical benefit rate (ORR+SD) was 72.4%, the 6-month progression-free survival (PFS) was 20.7%, and the 12-month overall survival (OS) was 34.5%. Two out of three patients who were wild type for BRAF, NRAS, and c-KIT mutations had confirmed partial responses, and one had a minor response.The recommended phase II dose is dasatinib 70 mg b.i.d with dacarbazine 800 mg m(-2). PFS and OS data for dasatinib at 70 mg b.i.d. with dacarbazine compared favourably with historical controls. Preliminary data support evaluating tumour mutation status further as a biomarker of response.

SUBMITTER: Algazi AP 

PROVIDER: S-EPMC3251861 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.

Algazi A P AP   Weber J S JS   Andrews S C SC   Urbas P P   Munster P N PN   DeConti R C RC   Hwang J J   Sondak V K VK   Messina J L JL   McCalmont T T   Daud A I AI  

British journal of cancer 20111129 1


<h4>Background</h4>Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma.<h4>Methods</h4>Patients had ECOG performance status 0-2 and normal organ function. Dacarbazine was administered on day 1 and dasatinib on day 2 through 19 of each 21-day cycle. Both were escalated from 50 mg b.i.d. of dasatinib and 800 mg m(-2) of dacarbazine. Available pre-treatment biopsies were sequenced for B  ...[more]

Similar Datasets

| S-EPMC2569026 | biostudies-literature
| S-EPMC6279094 | biostudies-literature
| S-EPMC5652683 | biostudies-literature
| S-EPMC4612320 | biostudies-literature
| S-EPMC3844155 | biostudies-literature
| S-EPMC5078079 | biostudies-other
| S-EPMC4982774 | biostudies-literature
| S-EPMC3940067 | biostudies-literature
| S-EPMC5702465 | biostudies-literature
| S-EPMC5318966 | biostudies-literature